The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

High-grade serous ovarian carcinoma (HGSOC) is the deadliest of gynecological cancers due to its high recurrence rate and acquired chemoresistance. RAS/MEK/ERK pathway activation is linked to cell proliferation and therapeutic resistance, but the role of MEK1/2-ERK1/2 pathway in HGSOC is poorly inve...

Full description

Bibliographic Details
Main Authors: Mikhail S. Chesnokov, Imran Khan, Yeonjung Park, Jessica Ezell, Geeta Mehta, Abdelrahman Yousif, Linda J. Hong, Ronald J. Buckanovich, Akimasa Takahashi, Ilana Chefetz
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
high-grade serous ovarian carcinoma
cancer stem-like cells
MEK1/2
trametinib
proliferation
Online Access:https://www.mdpi.com/2072-6694/13/6/1369

Internet

https://www.mdpi.com/2072-6694/13/6/1369

Similar Items